Literature DB >> 11478488

Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

W C Su1, S C Shiesh, H S Liu, C Y Chen, N H Chow, X Z Lin.   

Abstract

The expression of several growth factors and K-ras gene mutation in bile were studied to better understand the pathogenesis and improve early diagnosis of bile duct cancers. Bile samples were collected from 12 cholangiocarcinomas (CLC), 10 ampullary cancers (APC), 3 gallbladder cancers (GBC), 7 pancreatic cancers (PNC), 9 biliary tract infection (BTI), 8 biliary stone disease (ST), and 5 normal controls (NC). The highest mean value of TGF-beta in bile was in patients with BTI; the mean levels of bFGF and PDGF were highest in CLC, and patients with APC and CLC had higher expression of HER2/Neu than other groups. In bile, a K-ras gene codon 12 mutation was found in 5 of 6 (83%) cases of CLC by the PCR-RFLP method. The results suggest overexpression of bFGF, PDGF, and HER2/Neu and the presence of K-ras mutation are important for carcinogenesis of bile duct cancers, and detection of the above abnormalities in bile is helpful for early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478488     DOI: 10.1023/a:1010619316436

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  A clinical study of 130 patients with biliary tract cancers and periampullary tumors.

Authors:  W C Su; K K Chan; X Z Lin; P W Lin; N H Chow; J S Shin; C Y Chen; C J Tsao
Journal:  Oncology       Date:  1996 Nov-Dec       Impact factor: 2.935

Review 2.  Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies.

Authors:  S L Friedman
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

3.  Mutations of the DPC4/Smad4 gene in biliary tract carcinoma.

Authors:  S A Hahn; D Bartsch; A Schroers; H Galehdari; M Becker; A Ramaswamy; I Schwarte-Waldhoff; H Maschek; W Schmiegel
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

Review 4.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

5.  Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.

Authors:  N H Chow; S M Huang; S H Chan; L R Mo; M H Hwang; W C Su
Journal:  Anticancer Res       Date:  1995 May-Jun       Impact factor: 2.480

6.  Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma.

Authors:  N H Chow; K S Cheng; P W Lin; S H Chan; W C Su; Y N Sun; X Z Lin
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

7.  K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis.

Authors:  M Imai; T Hoshi; K Ogawa
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

8.  Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis.

Authors:  M Yukawa; T Fujimori; D Hirayama; Y Idei; T Ajiki; K Kawai; R Sugiura; S Maeda; K Nagasako
Journal:  Hum Pathol       Date:  1993-01       Impact factor: 3.466

9.  Hepatolithiasis in East Asia. Retrospective study.

Authors:  F Nakayama; R D Soloway; T Nakama; K Miyazaki; H Ichimiya; P C Sheen; C G Ker; G B Ong; T K Choi; J Boey
Journal:  Dig Dis Sci       Date:  1986-01       Impact factor: 3.199

10.  A reappraisal of cholangiocarcinoma in patient with hepatolithiasis.

Authors:  M F Chen; Y Y Jan; C S Wang; T L Hwang; L B Jeng; S C Chen; T J Chen
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

View more
  17 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 2.  Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2011-04

3.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors:  Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

4.  HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.

Authors:  Hee Jin Lee; Joon-Yong Chung; Stephen M Hewitt; Eunsil Yu; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2012-10-02       Impact factor: 4.064

5.  Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital.

Authors:  Yi-Yin Jan; Chun-Nan Yeh; Ta-Sen Yeh; Tse-Ching Chen
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

6.  Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma.

Authors:  Yi-Yin Jan; Chun-Nan Yeh; Ta-Sen Yeh; Tsann-Long Hwang; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-07       Impact factor: 3.352

7.  Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer.

Authors:  Iván Roa; Gonzalo de Toro; Kurt Schalper; Xabier de Aretxabala; Chaitanya Churi; Milind Javle
Journal:  Gastrointest Cancer Res       Date:  2014-03

8.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

Review 9.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 10.  Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms.

Authors:  Alphonse E Sirica; Catherine I Dumur; Deanna J W Campbell; Jorge A Almenara; Olorunseun O Ogunwobi; Jennifer L Dewitt
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.